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hree Decades of Clinical
rials With Beta-Blockers
he Contribution of the CAPRICORN
rial and the Effect of Carvedilol on
erious Arrhythmias*
raig M. Pratt, MD, FACC
ouston, Texas
or the past three decades, the benefits of beta-blockers
ave been investigated in patients surviving acute myocar-
ial infarction (AMI). Thanks to pioneering studies such as
hose in Scandinavia (timolol) (1), North America
propranolol—Beta-Blocker Heart Attack Trial [BHAT])
2), and Europe (atenolol—First International Study of
nfarct Survival [ISIS-I]) (3), a very compelling case was
ade by the mid-1980s for the use of beta-blockers in all
ppropriate post-AMI patients. The inclusion criteria for
hese trials were stable AMI patients. Patients with overt
ongestive heart failure (CHF) were excluded. Total mor-
ality was reduced in all three trials, as well as death
lassified as “sudden.” Since the mid-1980s, the prolifera-
ion of new therapies for the treatment of myocardial
nfarction and coronary artery disease raises the question of
elevance of these trials to contemporary therapy.
See page 525
At about the same time, the pathophysiology of clinical
HF due to left ventricular systolic dysfunction was clari-
ed, and additional therapies focused on specific neuroen-
ocrine targets. The angiotensin-converting enzyme (ACE)
nhibitors, followed by angiotensin receptor blockers and
pironolactone, were extensively studied and demonstrated
o reduce mortality (4–6). Beta-blocker trials were subse-
uently extended from the postmyocardial infarction to the
eart failure population. In the last 10 years, the U.S.
arvedilol trials (7), Carvedilol Prospective Randomized
umulative Survival (COPERNICUS) (8), and Effect of
arvedilol on Outcome After Myocardial Infarction in
atients with Left Ventricular Dysfunction (CAPRI-
ORN) (9), all explored the benefits of the selective
eta-blocker, carvedilol, in the polypharmacy environment
f patients with heart failure. The former two studies were
n heart failure populations with reduced left ventricular
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Methodist DeBakey Heart Center and Baylor College of Medicine,
ouston, Texas.jection fraction (LVEF); the CAPRICORN trial studied a
ost-AMI population with low LVEF (40%).
The CAPRICORN trial is the focus here, which con-
isted of patients with AMI within 5 to 21 days, and an
VEF 40% (9). Carvedilol was given in a dose escalation
ashion ranging from 6.25 mg to 25 mg twice a day. The
APRICORN trial was well executed and balanced for risk
t baseline. Importantly, almost all patients (98%) were
aking an ACE inhibitor, and nearly one-half had received
hrombolysis and/or primary angioplasty. Although the trial
ailed on its prespecified primary end point (all-cause
ortality plus cardiovascular hospitalization: hazard ratio
.92 [95% confidence interval 0.80 to 1.07]; p  0.30),
ll-cause mortality was reduced 23% (p  0.03) (9). New
xploratory analyses on arrhythmia frequency are presented
y McMurray et al. (10) in this issue of the Journal. An
vents committee blinded to treatment assignment verified
rrhythmic events. In brief, the authors report a 59%
eduction of atrial fibrillation/atrial flutter and a 76% reduc-
ion of ventricular tachycardia/ventricular fibrillation or
utter events in carvedilol-assigned compared with placebo-
ssigned patients. The arrhythmia reduction in carvedilol-
ssigned patients was consistent whether estimated as an
ntention-to-treat analysis or considering only patients
ithout a history of preceding arrhythmia. The consistency
f evidence from the CAPRICORN study, despite missing
ts primary end point, is that carvedilol is still beneficial
fter AMI therapy in the era of ACE inhibitors and
nterventional therapies (7). In fact, all-cause mortality
as reduced by a magnitude (23%) nearly identical to the
esults using propranolol in the BHAT, published 22
ears ago (2). “The more things change, the more they
tay the same.”
What are the mechanisms by which carvedilol mitigates
trial and ventricular arrhythmias? Carvedilol blocks both
eta1- and beta2-receptors. Unlike many other beta-
lockers, carvedilol also possesses antioxidant, alpha-
drenergic blockade, and antiendothelin effects (7,8) and, in
nimal models, is reported to block the HERG potassium
hannel (11). Regardless of which of these mechanisms
re operative, it is also important to consider indirect
ong-term hemodynamic effects of carvedilol, which may be
ivotal in explaining the decrease in arrhythmias. These
nclude a substantial increase in LVEF (by as much as 10%,
bsolute), decreased systolic and diastolic volumes, and,
resumably, lower left ventricular filling pressure and left
trial mean pressure. The attenuation of remodeling by
arvedilol on background therapy of ACE inhibition could
e a major factor in decreasing atrial and ventricular
rrhythmias.
A key focus is the interrelationships between arrhythmias,
VEF, and clinical CHF. The degree of systolic dysfunc-
ion is related to the extent of atrial and ventricular
rrhythmias, a relationship long recognized from clinical
rials (12) and from epidemiologic studies (13). The inci-
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Editorial Comment February 15, 2005:531–2ence of atrial fibrillation in a heart failure population is
elated to the degree of CHF and LVEF. A stellar example
s from the Danish Investigations of Arrhythmia and
ortality on Dofetilide (DIAMOND) trials (myocardial
nfarction and CHF) (14,15) where the entrance require-
ent for LVEF was identical (35%), but the postmyocar-
ial infarction population had an incidence of atrial fibril-
ation only one-quarter of the DIAMOND CHF trial
opulation (7% vs. 27%) despite a small difference in mean
VEF (14,15). In the DIAMOND CHF trial, dofetilide-
ssigned patients had a reduction in atrial fibrillation that
as associated with a reduction in heart failure hospitaliza-
ion (15). Although this was a post-hoc analysis of the
IAMOND-CHF trial that did not meet its primary end
oint (all-cause mortality), it demonstrates the potential
linical importance of the interaction of atrial fibrillation
nd the degree of CHF.
Whether HERG potassium channel blockade plays a
eaningful role in explaining the carvedilol-associated atrial
brillation/flutter reduction is not known (11). A trial
elevant to this possibility is the Azimilide Postinfarct
urvival Evaluation (ALIVE), in which azimilide resulted
n a reduction in recurrent or new atrial fibrillation (16).
his was a prespecified analysis of a post-AMI population
ith LVEF 35% in whom nearly 90% of patients were on
CE and two-thirds of the patients were taking beta-
lockers, randomly assigned to azimilide (an IKr and IKs
locker) versus placebo.
What about the reduction in ventricular tachycardia, ven-
ricular fibrillation, and flutter in the CAPRICORN study?
gain, history is revealing. A landmark epidemiologic study of
atients after AMI by Bigger and colleagues (13) more than 25
ears ago established that, as LVEF decreases, the extent and
omplexity of ventricular arrhythmias increases. In the Cardiac
rrhythmia Suppression Trial (CAST), ventricular arrhythmia
uppression on antiarrhythmic therapy was more complete in
atients with a preserved LVEF (12). It is a reasonable
peculation that the reduction in ventricular arrhythmias in
arvedilol-assigned patients is related to the beneficial effects of
emodeling in the CAPRICORN trial. It is important to
eemphasize that this was accomplished on a uniform back-
round of ACE therapy (9).
We can expect the playing field of clinical trials in AMI and
HF to be conducted on increasingly complex background
herapy. Despite the numerous additions to “required” thera-
ies, the place of beta-blockers in the post-AMI population
emains solid. The extension of beta-blockers to patients with
eft ventricular systolic dysfunction and symptomatic heart
ailure is also firmly established. Yet beta-blockers are still not
s widely used as the data merits; why? One of the goals of the
APRICORN investigations was to reestablish the role of
eta-blockers in the vastly more complicated post-AMI ther-
peutic environment now facing clinicians. They accomplished
heir goal. So far the science of our clinical trials of beta-
lockers has produced excellent results, whereas the publicealth goal of having all appropriate patients taking them has
ad more modest success.
eprint requests and correspondence: Dr. Craig M. Pratt, The
ethodist Hospital, Department of Medicine, 6565 Fannin, Mail
tation F1001, Houston, Texas 77030. E-mail: cpratt@bcm.tmc.edu.
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